Transplantation

• 

  Publication Venue For

  • Dendritic Cell Therapy in Transplantation, Phenotype Governs Destination and Function..  102:1593-1594. 2018
  • Differential Role of B Cells and IL-17 Versus IFN-γ During Early and Late Rejection of Pig Islet Xenografts in Mice..  101:1801-1810. 2017
  • Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients.  101:657-663. 2017
  • Organ Transplantation in Greece..  100:1589-1591. 2016
  • Cryptococcosis in Patients With Cirrhosis of the Liver and Posttransplant Outcomes.  99:2132-2141. 2015
  • Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial..  99:1003-1008. 2015
  • Surveillance of Nonmelanoma Skin Cancer Incidence Rates in Kidney Transplant Recipients in Ireland.  98:646-652. 2014
  • Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice..  97:1216-1224. 2014
  • Renal paratransplant hernia. An uncommon variant of internal hernia. Are we aware of it?.  97:e65-e66. 2014
  • Liver transplantation for liver malignancies in Wilson's disease: two novel cases..  97:e35-e36. 2014
  • Mouse Flk-1+Sca-1- Mesenchymal Stem Cells.  97:509-517. 2014
  • Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies..  97:227-234. 2014
  • An uncommon presentation of non-Hodgkin's lymphoma in a renal transplant recipient..  95:e66-e67. 2013
  • Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts..  95:919-927. 2013
  • Significantly Greater Hazard Associated with the Use of Older Donor Livers in HCV+ Recipients.  94:107-107. 2012
  • Significantly Greater Hazard Associated with the Use of Older Donor Livers in HCV+ Recipients.  94:426-426. 2012
  • The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables..  94:197-203. 2012
  • Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis..  93:737-743. 2012
  • Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients..  93:319-324. 2012
  • Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort..  92:543-549. 2011
  • Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients..  92:346-350. 2011
  • Are HIV-infected donors suitable for renal transplantation?.  91:e22-e23. 2011
  • Potential Risk in Using Hepatic Veins of a Native Liver for Reconstructing Accessory Veins in Right Lobe Living Donor Graft.  88:143-144. 2009
  • Donor Risk in Adult-to-Adult Living Donor Liver Transplantation: Impact of Left Lobe Graft.  87:445-450. 2009
  • Impact of Des-Gamma-Carboxy Prothrombin and Tumor Size on the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation.  87:531-537. 2009
  • Response: The impracticality of overriding family rejection of donation.  86:1631-1632. 2008
  • A Simple Hilar Dissection Technique Preserving Maximum Blood Supply to the Bile Duct in Living Donor Liver Transplantation.  86:1468-1469. 2008
  • The Timing of Liver Transplantation After Primary Hepatectomy for Hepatocellular Carcinoma: A Special Reference to Recurrence Pattern and Milan Criteria.  86:641-646. 2008
  • Comparison of short bowel syndrome acquired early in life and during adolescence..  86:63-66. 2008
  • A gift of life: ethical and practical problems with conditional and directed donation..  85:1542-1544. 2008
  • Collaborative strategies to reduce mortality and morbidity in patients with chronic intestinal failure including those who are referred for small bowel transplantation..  85:1378-1384. 2008
  • Differential impact of CD154 costimulation blockade on alloreactive effector and regulatory T cells in murine renal transplant recipients..  85:1332-1338. 2008
  • Holmium:yttrium-aluminum-garnet laser endoureterotomy for the treatment of transplant kidney ureteral strictures..  85:1318-1321. 2008
  • Repeat surgical bowel lengthening with the STEP procedure..  85:1294-1299. 2008
  • Effect of CXCL-1/KC production in high risk vascularized corneal allografts on T cell recruitment and graft rejection..  85:615-625. 2008
  • A new T-cell receptor transgenic model of the CD4+ direct pathway: level of priming determines acute versus chronic rejection..  85:247-255. 2008
  • Assessment of Graft Fibrosis by Transient Elastography in Patients With Recurrent Hepatitis C After Living Donor Liver Transplantation.  85:69-74. 2008
  • Human herpesvirus 7 primary infection in kidney transplant recipients..  85:298-302. 2008
  • Living Donor Liver Transplantation for Acute Liver Failure Using Left Lobe Grafts.  85:160-161. 2008
  • Alemtuzumab..  84:1545-1547. 2007
  • Beneficial Effects of Hyperbaric Oxygen Pretreatment on Massive Hepatectomy Model in Rats.  84:1656-1661. 2007
  • Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts (Transplantation (2007) 83, (1643)).  84:1375. 2007
  • Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide..  84:1012-1019. 2007
  • Explanted Portal Vein Grafts for Middle Hepatic Vein Tributaries in Living-Donor Liver Transplantation.  84:836-841. 2007
  • Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation..  83:1429-1434. 2007
  • Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts..  83:1643-1647. 2007
  • The influence of innate immunity gene receptors polymorphisms in renal transplant infections..  83:1493-1500. 2007
  • CD154 blockade, sirolimus, and donor-specific transfusion prevents renal allograft rejection in cynomolgus monkeys despite homeostatic T-cell activation..  83:1219-1225. 2007
  • Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients..  83:1027-1034. 2007
  • Extended Indication for Living Donor Liver Transplantation in Patients With Hepatocellular Carcinoma.  83:893-899. 2007
  • Venous sinus thrombosis in a renal transplant patient..  83:825-827. 2007
  • Utility of a mathematical nomogram to predict delayed graft function: a single-center experience-critique..  83:524-525. 2007
  • A review of critical periods for opportunistic infection in the new transplantation era..  82:1457-1462. 2006
  • CD20+ Lymphocytes in Renal Allografts Are Associated with Poor Graft Survival in Pediatric Patients.  82:1769-1773. 2006
  • Postinfectious glomerulonephritis in renal allograft recipients..  82:1224-1228. 2006
  • Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma..  82:1136-1139. 2006
  • A prospective survey of human herpesvirus-6 primary infection in solid organ transplant recipients..  82:979-982. 2006
  • Impaired arterial compliance and aerobic endurance in kidney transplant recipients..  82:920-923. 2006
  • Induction immunosuppression..  82:593-602. 2006
  • Adult T-cell Leukemia Development From a Human T-cell Leukemia Virus Type I Carrier After a Living-Donor Liver Transplantation.  82:840-843. 2006
  • Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization..  82:289-290. 2006
  • Effect of an anti-C5a monoclonal antibody indicates a prominent role for anaphylatoxin in pulmonary xenograft dysfunction..  81:1686-1694. 2006
  • Depletion of pulmonary intravascular macrophages prevents hyperacute pulmonary xenograft dysfunction..  81:1157-1164. 2006
  • Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies..  81:1049-1057. 2006
  • Successful bilateral lung transplant outcomes in recipients 61 years of age and older..  81:862-865. 2006
  • Determination of the functional status of alloreactive T cells by interferon-gamma kinetics..  81:590-598. 2006
  • Composite tissue allotransplantation: classification of clinical acute skin rejection..  81:418-422. 2006
  • T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients..  81:81-87. 2006
  • Transplant tolerance: converging on a moving target..  81:1-6. 2006
  • Composite tissue allotransplantation: development of a preclinical model in nonhuman primates..  80:1447-1454. 2005
  • In Situ Dye Injection Bile Leakage Test of the Graft in Living Donor Liver Transplantation.  80:1398-1401. 2005
  • Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome..  80:1131-1133. 2005
  • Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection..  80:1033-1039. 2005
  • Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin..  80:1051-1059. 2005
  • Impact of Graft Hepatic Vein Inferior Vena Cava Reconstruction with Graft Venoplasty and Inferior Vena Cava Cavoplasty in Living Donor Adult Liver Transplantation Using a Left Lobe Graft.  80:964-968. 2005
  • Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole..  80:868-871. 2005
  • Short-Term Intensive Treatment for Donors with Hepatic Steatosis in Living-Donor Liver Transplantation.  80:608-612. 2005
  • Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation..  80:320-325. 2005
  • Half-life analysis of pancreas and kidney transplants..  80:272-275. 2005
  • Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection..  80:145-148. 2005
  • Sensitization with xenogeneic tissues alters the heavy chain repertoire of human anti-Galalpha1-3Gal antibodies..  80:102-109. 2005
  • Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations..  80:157-163. 2005
  • Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients..  79:1477-1483. 2005
  • Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin..  79:1634-1635. 2005
  • Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice..  79:1091-1096. 2005
  • Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients..  78:1765-1773. 2004
  • Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation..  78:1471-1478. 2004
  • The burden of acute renal failure in nonrenal solid organ transplantation..  78:1351-1355. 2004
  • Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine..  78:1002-1007. 2004
  • Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival..  78:1030-1035. 2004
  • Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction..  78:919-924. 2004
  • A SIMPLE AND ACCURATE FORMULA TO ESTIMATE LEFT HEPATIC GRAFT VOLUME IN LIVING-DONOR ADULT LIVER TRANSPLANTATION.  77:1571-1575. 2004
  • Lymphangiogenesis in tissue-engineered small intestine..  77:1162-1166. 2004
  • A highly selective inhibitor of IkappaB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection..  77:1090-1094. 2004
  • Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients..  77:795-800. 2004
  • Ethics in the quest for transplant tolerance..  77:947-951. 2004
  • Metastable tolerance in nonhuman primates and humans..  77:936-939. 2004
  • Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model..  77:914-920. 2004
  • Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients..  77:232-237. 2004
  • Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen..  76:1686-1690. 2003
  • Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients..  76:923-929. 2003
  • Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection..  76:524-530. 2003
  • Double genetic modification of adenovirus fiber with RGD polylysine motifs significantly enhances gene transfer to isolated human pancreatic islets..  76:252-261. 2003
  • Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model..  76:55-60. 2003
  • Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H)..  76:120-129. 2003
  • Use of steatotic graft in living-donor liver transplantation.  76:344-348. 2003
  • Prognostic significance of microvascular thrombosis in donor kidney allograft biopsies..  75:1847-1852. 2003
  • Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts..  75:1677-1682. 2003
  • Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection..  75:1490-1495. 2003
  • Underutilization of pancreas donors..  75:1271-1276. 2003
  • Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling..  75:1075-1077. 2003
  • Liver transplantation from a cadaver donor with ethylene-glycol-induced brain death..  75:1056. 2003
  • Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient..  75:730-732. 2003
  • BK virus and SV40 co-infection in polyomavirus nephropathy..  74:1497-1504. 2002
  • Piceatannol in combination with low doses of cyclosporine A prolongs kidney allograft survival in a stringent rat transplantation model..  74:1609-1617. 2002
  • The role of the porcine von Willebrand factor: baboon platelet interactions in pulmonary xenotransplantation..  74:1596-1603. 2002
  • Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation..  74:1365-1369. 2002
  • Prolonged survival of class II transactivator-deficient cardiac allografts..  74:1341-1348. 2002
  • Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area..  74:1381-1386. 2002
  • Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates..  74:940-943. 2002
  • Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury..  74:916-923. 2002
  • Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome..  74:799-804. 2002
  • Treatment of refractory acute rejection in a lung transplant recipient with campath 1H..  74:903-904. 2002
  • Tissue-engineered small intestine: ontogeny of the immune system..  74:619-623. 2002
  • Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent..  73:1933-1936. 2002
  • Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation..  73:1717-1723. 2002
  • FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506..  73:1835-1838. 2002
  • Determinants of willingness to donate living related and cadaveric organs: identifying opportunities for intervention..  73:1683-1691. 2002
  • Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report..  73:907-910. 2002
  • Short course induction immunosuppression with thymoglobulin for renal transplant recipients..  73:473-475. 2002
  • Rapamycin increases transforming growth factor-beta mRNA expression in immortalized rat proximal renal tubular cells..  73:319-320. 2002
  • Mechanisms of tolerance induced by PG490-88 in a bone marrow transplantation model..  73:115-121. 2002
  • Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease..  72:1924-1929. 2001
  • A new technique for combined liver/small intestinal transplantation..  72:1846-1848. 2001
  • Human platelets activate porcine endothelial cells through a CD154-dependent pathway..  72:1858-1861. 2001
  • Alternariosis after liver transplantation..  72:1840-1843. 2001
  • Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates..  72:1473-1478. 2001
  • Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes..  72:1444-1450. 2001
  • Treatment of multiple aneurysms of the splenic artery after liver transplantation by percutaneous embolization and laparoscopic splenectomy..  72:956-958. 2001
  • Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6..  72:720-726. 2001
  • Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids..  72:581-587. 2001
  • Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation..  72:666-670. 2001
  • Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients..  72:587-597. 2001
  • Candida fasciitis following renal transplantation..  72:477-479. 2001
  • Expanded criteria donors/high risk recipients is not always cheaper than hemodialysis..  72:554-555. 2001
  • Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18..  72:496-503. 2001
  • Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates..  72:377-384. 2001
  • Protective effects of ischemic preconditioning on the cold-preserved liver are tyrosine kinase dependent..  72:406-412. 2001
  • Safety of aerosolized amphotericin B lipid complex in lung transplant recipients..  72:545-548. 2001
  • Studies of Pediatric Liver Transplantation (SPLIT): year 2000 outcomes..  72:463-476. 2001
  • Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection..  71:1772-1776. 2001
  • Reconsideration of HIV as a contraindication to transplantation..  71:1689. 2001
  • Guillain-Barre syndrome in organ and bone marrow transplant patients..  71:1169-1172. 2001
  • Lack of utility of intestinal fatty acid binding protein levels in predicting intestinal allograft rejection..  71:1058-1060. 2001
  • Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation..  71:892-895. 2001
  • Dobutamine stress echocardiography for orthotopic liver transplant evaluation..  71:818. 2001
  • Biophysical characteristics of anti-Gal(alpha)1-3Gal IgM binding to cell surfaces: implications for xenotransplantation..  71:440-446. 2001
  • CYCLOPHOSPHAMIDE-INDUCED TOLERANCE IN RAT ORTHOTOPIC LIVER TRANSPLANTATION1.  71:447-456. 2001
  • Antigen expression in xenotransplantation: how low must it go?.  71:313-319. 2001
  • V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion..  71:193-198. 2001
  • A human CD46 transgenic pig model system for the study of discordant xenotransplantation..  71:132-142. 2001
  • The role of anti-Galalpha1-3Gal antibodies in acute vascular rejection and accommodation of xenografts..  70:1667-1674. 2000
  • Extracorporeal liver perfusion using human and pig livers for acute liver failure..  70:1472-1478. 2000
  • Laparoscopic donor nephrectomy: pro..  70:1544-1546. 2000
  • Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion..  70:1442-1447. 2000
  • BENEFICIAL EFFECT OF FR167653 ON COLD ISCHEMIA/REPERFUSION INJURY IN RAT LIVER TRANSPLANTATION1.  70:1318-1322. 2000
  • Finding a place for public preferences in liver allocation decisions..  70:1411-1413. 2000
  • DOMINO LIVER TRANSPLANTATION FROM A LIVING RELATED DONOR.  70:1236-1239. 2000
  • Increased glomerular deposits of von Willebrand factor in chronic, but not acute, rejection of primate renal allografts..  70:877-886. 2000
  • Long-term results of liver transplantation in older patients 60 years of age and older..  70:780-783. 2000
  • Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension..  70:548-550. 2000
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity..  70:162-167. 2000
  • Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients..  69:2360-2366. 2000
  • Altered intragraft immune responses and improved renal function in MHC class II-deficient mouse kidney allografts..  69:2137-2143. 2000
  • Contralateral inflow occlusion to optimize graft volume and to reduce blood loss during parenchymal dissection in living-related liver transplantation..  69:2232. 2000
  • Laparoscopic donor nephrectomy increases the supply of living donor kidneys: a center-specific microeconomic analysis..  69:2211-2213. 2000
  • Microcapsule stabilization with sodium sulfate pretreatment..  69:S209-S209. 2000
  • Primate allotransplantation using costimulation blockade..  69:S414-S414. 2000
  • Renin-angiotensin system gene expression in post-transplant hypertension predicts allograft function..  69:1485-1491. 2000
  • Tumor necrosis factor-alpha and tumor growth factor-beta1 genotype: partial association with intragraft gene expression in two cases of long-term peripheral tolerance to a kidney transplant..  69:1527-1530. 2000
  • Long-term outcome of simultaneous kidney-pancreas transplantation: analysis of 61 patients with more than 5 years follow-up..  69:550-555. 2000
  • Disaccharidase activities and fat assimilation in pediatric patients after intestinal transplantation..  69:362-365. 2000
  • Bile acids in xenogeneic ex-vivo liver perfusion: function of xenoperfused livers and compatibility with human bile salts and porcine livers..  69:242-248. 2000
  • Effect of surrogate tolerogenesis on the vascular rejection of pig heart xenografts..  69:232-235. 2000
  • Outcome in recipients of dual kidney transplants: an analysis of the dual registry patients..  69:281-285. 2000
  • Outcomes of laparoscopic donor nephrectomy in obese patients..  69:180-182. 2000
  • Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function..  68:1578-1582. 1999
  • Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients..  68:1279-1288. 1999
  • Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients..  68:1125-1131. 1999
  • Is living donor nephrectomy a "23-hr stay" procedure?.  68:1064-1065. 1999
  • The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles..  68:1044-1050. 1999
  • The human bone marrow as an immunoregulatory organ..  68:1079-1090. 1999
  • Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method..  68:825-832. 1999
  • Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies..  68:693-698. 1999
  • Laparoscopic versus open donor nephrectomy: comparing ureteral complications in the recipients and improving the laparoscopic technique..  68:497-502. 1999
  • Biliary secretion of extracorporeal porcine livers with single and dual vessel perfusion..  68:362-368. 1999
  • Calpain inhibition prevents sinusoidal endothelial cell apoptosis in the cold ischemic rat liver..  68:136-140. 1999
  • The impact of hypoalbuminemia in kidney-pancreas transplant recipients..  68:72-75. 1999
  • EFFECTS OF DELETION VARIANT OF HEPATOCYTE GROWTH FACTOR ON REDUCED-SIZE LIVER TRANSPLANTATION IN RATS1,2.  68:39-44. 1999
  • Microchimerism in sensitized renal patients..  67:1381-1383. 1999
  • CENTRAL TOLERANCE IS NOTA SIGNIFICANT MECHANISM FOR PROLONGED ALLOGRAFT SURVIVAL IN ANTI-CD3 IMMUNOTOXIN TREATED MONKEYS.  67:S557-S557. 1999
  • PEDIATRIC RECIPIENTS OF LIVERS FROM FEMALE DONORS ARE AT GREATER RISK FOR HEPATIC ARTERY THROMBOSIS (HAT).  67:S635-S635. 1999
  • Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver..  67:1099-1105. 1999
  • Portopulmonary hypertension and the liver transplant candidate..  67:1087-1093. 1999
  • Renal transplantation in recipients over the age of 60: the impact of donor age..  67:1191-1193. 1999
  • A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients..  67:1011-1018. 1999
  • Iliac artery pseudoaneurysm following renal transplantation presenting as lumbosacral plexopathy..  67:1077-1078. 1999
  • A SURVEY OF MALE SEXUAL FUNCTION FOLLOWING PANCREAS TRANSPLANTATION.  67:S174-S174. 1999
  • CHANGING DONOR AND RECIPIENT DEMOGRAPHICS AFFECTS LONG-TERM RENAL ALLOGRAFT OUTCOME.  67:S219-S219. 1999
  • DIAGNOSIS AND CLINICAL COURSE OF BK POLYOMAVIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS..  67:S217-S217. 1999
  • Downregulation of CD28- and T cell Antigen Receptor-Mediated T Cell Activation by Protein Kinase C-Stimulated Tyrosine Phosphatases..  67:S130-S130. 1999
  • FRACTALKINE EXPRESSION IS UPREGULATED IN RENAL ALLOGRAFT REJECTION.  67:S47-S47. 1999
  • Immunotoxin FN18-CRM9 is Superior to the Unconjugated Monoclonal Antibody (FN18) in Inducing Protein Tyrosine Phosphorylation and CD3 Internalization..  67:S263-S263. 1999
  • THE DEVELOPMENT OF POST TRANSPLANT ERYTHROCYTOSIS IN HYPERCALCEMIC RENAL TRANSPLANT PATIENTS.  67:S169-S169. 1999
  • The Aggregation of the T Cell Costimulatory Molecule CD28 Induces Tyrosine Phosphorylation of the Protein Tyrosine Kinase Pyk2..  67:S229-S229. 1999
  • A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients..  67:411-415. 1999
  • Pediatric renal transplantation under tacrolimus-based immunosuppression..  67:299-303. 1999
  • A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation..  66:1751-1759. 1998
  • Posttransplant infection in enteric versus bladder-drained simultaneous pancreas-kidney transplant recipients..  66:1746-1750. 1998
  • Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data..  66:1193-1200. 1998
  • Outcome of liver transplantation in critically ill patients with alcoholic cirrhosis: survival according to medical variables and sobriety..  66:298-302. 1998
  • Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9..  66:5-13. 1998
  • Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation..  66:29-37. 1998
  • Complement-mediated pulmonary xenograft injury: studies in swine-to-primate orthotopic single lung transplant models..  65:1084-1093. 1998
  • Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients..  65:956-965. 1998
  • Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension..  65:457-459. 1998
  • Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients..  65:242-248. 1998
  • A novel approach to the treatment of chronic allograft nephropathy..  64:1706-1710. 1997
  • Posttransplant diastolic hypertension: associations with intragraft transforming growth factor-beta, endothelin, and renin transcription..  64:1716-1720. 1997
  • Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease..  64:1781-1786. 1997
  • Does transplantation produce quality of life benefits? A quantitative analysis of the literature..  64:1261-1273. 1997
  • Outcome after splenic vein thrombosis in the pancreas allograft..  64:933-935. 1997
  • A technique for management of multiple renal arteries after laparoscopic donor nephrectomy..  64:779-780. 1997
  • Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system..  63:1579-1586. 1997
  • Safe pancreas transplantation in patients with coronary artery disease..  63:1294-1299. 1997
  • Split tolerance induced by immunotoxin in a rhesus kidney allograft model..  63:1339-1345. 1997
  • Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA..  63:1278-1286. 1997
  • A case of disseminated infection with Nocardia brasiliensis in a lung transplant recipient..  63:1189-1190. 1997
  • Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts..  63:900-902. 1997
  • Successful emergency transplantation of a liver allograft from a donor maintained on extracorporeal membrane oxygenation..  63:910-911. 1997
  • Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension..  63:604-606. 1997
  • Prevention of autoimmune islet allograft destruction by engraftment of donor T cells..  63:299-303. 1997
  • Simultaneous pancreas/kidney transplantation--a comparison of enteric and bladder drainage of exocrine pancreatic secretions..  63:238-243. 1997
  • Weaning of immunosuppression in liver transplant recipients..  63:243-249. 1997
  • FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts..  63:1-6. 1997
  • Gastrointestinal bleeding after liver transplantation..  63:60-67. 1997
  • Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis..  62:1758-1762. 1996
  • Antioxidant lazaroid U-74006F improves renal function and reduces the expression of cytokines, inducible nitric oxide synthase, and MHC antigens in a syngeneic renal transplant model. Partial support for the response-to-injury hypothesis..  62:1628-1633. 1996
  • Double renal allografts successfully increase utilization of kidneys from older donors within a single organ procurement organization..  62:1581-1583. 1996
  • "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression..  62:1242-1246. 1996
  • Adenovirus-mediated gene transfer into rat cardiac allografts (vol 61, pg 1726, 1996).  62:1038-1038. 1996
  • Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts..  62:1018-1023. 1996
  • Molecular barriers to xenotransplantation..  62:303-310. 1996
  • Fulminant hepatic failure from the Budd-Chiari syndrome. A bridge to transplantation with transjugular intrahepatic portosystemic shunt..  62:294-296. 1996
  • The intragraft CD8+ T cell response in renal allograft rejection in the mouse..  62:96-104. 1996
  • Adenovirus-mediated gene transfer into rat cardiac allografts. Comparison of direct injection and perfusion..  61:1726-1729. 1996
  • Determinants of graft survival after renal transplantation..  61:1581-1586. 1996
  • Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model..  61:1222-1228. 1996
  • The use of bilateral adult renal allografts - a method to optimize function from donor kidneys with suboptimal nephron mass..  61:1261-1263. 1996
  • Intracardiac thrombus formation during orthotopic liver transplantation: a new entity or an old enemy?.  61:1131. 1996
  • Identification and characterization of a galactosyl peptide mimetic. Implications for use in removing xenoreactive anti-A Gal antibodies..  61:851-855. 1996
  • Rhodococcus equi infection after liver transplantation..  61:980-982. 1996
  • CO2 angiography--a technique for vascular imaging in renal allograft dysfunction..  61:652-654. 1996
  • Functional activity of anti-C6 antibodies elicited in C6-deficient rats reconstituted by liver allografts. Ability to inhibit hyperacute rejection of discordant cardiac xenografts..  61:588-594. 1996
  • Cellular localization and effect of nitric oxide synthesis in a rat model of orthotopic liver transplantation..  61:305-312. 1996
  • The influence of native nephrectomy on the incidence of recurrent disease following renal transplantation for primary glomerulonephritis..  61:228-234. 1996
  • Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience..  61:54-61. 1996
  • Combined simultaneous kidney/bone marrow transplantation..  60:1421-1425. 1995
  • Experience with protocol biopsies after solitary pancreas transplantation..  60:1431-1437. 1995
  • Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients..  60:1546-1554. 1995
  • Pretransplant status and patient survival following liver transplantation..  60:920-925. 1995
  • Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11)..  60:828-835. 1995
  • The humoral immune response in humans following cross-perfusion of porcine organs..  60:861-868. 1995
  • Newborn baboon serum anti-alpha galactosyl antibody levels and cytotoxicity to cultured pig kidney (PK15) cells..  60:520-521. 1995
  • A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants..  60:55-58. 1995
  • Variation in the level of xenoantigen expression in porcine organs..  59:1589-1596. 1995
  • Newborn baboon serum lacks natural anti-pig xenoantibody..  59:1189-1194. 1995
  • Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation..  59:1010-1014. 1995
  • Successful extrarenal transplantation from non-heart-beating donors..  59:977-982. 1995
  • Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients..  59:847-851. 1995
  • Complement in organ transplantation. Contributions to inflammation, injury, and rejection..  59:797-808. 1995
  • Rejection of kidney allografts by MHC class I-deficient mice..  59:746-755. 1995
  • Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement..  59:655-661. 1995
  • A prospective randomized trial of FK506-based immunosuppression after renal transplantation..  59:485-490. 1995
  • Obesity as a risk factor following renal transplantation..  59:631-633. 1995
  • The use of spiral computed tomography in the evaluation of living donors for kidney transplantation..  59:643-645. 1995
  • Absence of hyperacute rejection in pig-to-primate orthotopic pulmonary xenografts..  59:410-416. 1995
  • Pharmaceutical expenses after kidney and kidney-pancreas transplantation..  59:452-453. 1995
  • Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis..  59:135-138. 1995
  • Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts..  59:1-6. 1995
  • Abrogation of baboon natural xenoantibody to pig splenocytes by DL-penicillamine..  58:1299-1303. 1994
  • Mechanisms of injury in porcine livers perfused with blood of patients with fulminant hepatic failure..  58:1162-1171. 1994
  • A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients..  58:779-785. 1994
  • Endovascular stenting of the abdominal aorta following renal transplantation..  58:522-524. 1994
  • Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation..  58:23-27. 1994
  • Hematopoietic chimerism achieved by in utero hematopoietic stem cell injection does not induce donor-specific tolerance for renal allografts in sheep..  58:110-111. 1994
  • Induction of specific tolerance by intrathymic injection of recipient muscle cells transfected with donor class I major histocompatibility complex..  57:990-996. 1994
  • Enhancement of the recovery of rat hearts after prolonged cold storage by cyclocreatine phosphate..  57:803-806. 1994
  • Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow..  57:852-856. 1994
  • SPIRAL COMPUTED-TOMOGRAPHY IN THE DIAGNOSIS OF TRANSPLANT RENAL-ARTERY STENOSIS.  57:746-748. 1994
  • Use of spiral computed tomography in the diagnosis of transplant renal artery stenosis..  57:746-748. 1994
  • The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts..  57:363-370. 1994
  • Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity..  56:1422-1426. 1993
  • The effect of xenoreactive antibody and B cell depletion on hyperacute rejection of guinea pig-to-rat cardiac xenografts..  56:1318-1324. 1993
  • Alterations in renal interleukin-1 production during kidney transplant rejection in the rat. The effects of high-dose methylprednisolone..  56:1157-1162. 1993
  • Ex vivo characterization of human anti-porcine hyperacute cardiac rejection..  56:785-793. 1993
  • The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses..  56:672-680. 1993
  • Astrocyte cytolysis by MHC class II-specific mouse T cell clones..  56:393-399. 1993
  • Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma..  55:1425-1428. 1993
  • The effects of surgery and acute rejection on glomerular hemodynamics in the transplanted rat kidney..  55:1219-1224. 1993
  • Characterization of human anti-porcine "natural antibodies" recovered from ex vivo perfused hearts--predominance of IgM and IgG2..  55:1144-1150. 1993
  • Retransplantation of the liver--a seven-year experience..  55:1083-1087. 1993
  • The effect of bursectomy on natural xenoreactive antibodies and vascularized rat cardiac xenograft rejection in the chicken..  55:1139-1144. 1993
  • Frequency of kidney rejection in diabetic patients undergoing simultaneous kidney and pancreatic islet cell transplantation..  55:761-764. 1993
  • Risk factors for primary dysfunction after liver transplantation--a multivariate analysis..  55:807-813. 1993
  • The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness..  55:924-931. 1993
  • Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors. Issues of quality of life..  55:551-557. 1993
  • Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody..  54:844-851. 1992
  • Thromboxane augmentation of alloreactive T cell function..  54:498-505. 1992
  • The effects of donor-specific blood transfusion enhancement of rat renal allografts on host NK cell responses..  54:136-142. 1992
  • The effects of liver denervation on the regulation of hepatic biliary secretion..  54:129-136. 1992
  • Gene transfer and expression in rat cardiac transplants..  53:703-705. 1992
  • The influence of RS-61443 on antibody-mediated rejection..  53:699-701. 1992
  • Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance..  53:329-338. 1992
  • The effect of donor age, recipient age, and HLA match on immunologic graft survival in cadaver renal transplant recipients..  53:55-59. 1992
  • Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation..  52:1014-1019. 1991
  • Evaluation of solutions for small intestinal preservation. Biochemical changes as a function of storage time..  52:794-799. 1991
  • The effect of soluble complement receptor type 1 on hyperacute xenograft rejection..  52:868-873. 1991
  • Bile compositional changes and cholesterol stone formation following orthotopic liver transplantation..  52:727-730. 1991
  • Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine..  52:634-640. 1991
  • Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies..  51:443-447. 1991
  • Multivariate analysis of donor-specific versus random transfusion protocols in haploidentical living-related transplants..  51:382-384. 1991
  • Orthotopic liver transplantation in patients 60 years of age and older..  51:431-433. 1991
  • The effects of donor-specific blood transfusion enhancement of rat renal allografts on cytotoxic activity and phenotypes of peripheral blood lymphocytes, splenocytes, and graft-infiltrating cells..  51:451-459. 1991
  • The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation..  51:157-163. 1991
  • Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up..  50:589-593. 1990
  • A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease..  50:49-54. 1990
  • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect..  50:175-177. 1990
  • Significant prolongation of hamster liver transplant survival in Lewis rats by total-lymphoid irradiation, cyclosporine, and splenectomy..  49:13-17. 1990
  • Association of chronic thromboxane inhibition with reduced in situ cytotoxic T cell activity in rejecting rat renal allografts..  48:660-666. 1989
  • Mediation of hyperacute rejection of rat hepatic allografts by RT-1 antigens..  48:723-725. 1989
  • Similarities in long-term alloreactive T cell lines propagated from transfusion-enhanced and control-rejecting rat renal allografts..  47:390-394. 1989
  • Variable allograft responses to pretreatment with donor splenocytes treated with mitomycin C in the rat..  47:360-363. 1989
  • The role of class I major histocompatibility complex antigens in prolonging the survival of hepatic allografts in the rat..  47:171-177. 1989
  • Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support..  46:57-60. 1988
  • Effect of dietary fish oil supplementation on eicosanoid production by rat renal allografts..  45:470-474. 1988
  • Comparison of intravenous digital subtraction angiography and conventional arteriography in defining renal anatomy..  45:56-58. 1988
  • Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection..  45:1-7. 1988
  • Determinants of the source of cytomegalovirus in murine renal allograft recipients..  44:636-639. 1987
  • Transplantation of the entire small bowel in inbred rats using cyclosporine..  43:478-484. 1987
  • Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity..  43:282-285. 1987
  • Infiltrating cell phenotypes and patterns associated with hepatic allograft rejection or acceptance..  43:169-172. 1987
  • Xenograft survival in two species combinations using total-lymphoid irradiation and cyclosporine..  43:173-175. 1987
  • Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection..  43:8-12. 1987
  • Development of bullous pemphigoid after allogeneic bone marrow transplantation. Report of a case..  42:320-322. 1986
  • Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation..  41:583-586. 1986
  • Cyclosporine-associated microangiopathy in renal transplantation: a severe but potentially reversible form of early graft injury..  41:541-544. 1986
  • Renal allograft cell infiltrates associated with irreversible rejection..  40:679-685. 1985
  • Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone..  40:162-166. 1985
  • Transmission of latent cytomegalovirus in a murine kidney tissue transplantation model..  39:290-296. 1985
  • Rapid serologic diagnosis of serum sickness from antithymocyte globulin therapy using enzyme immunoassay..  38:582-586. 1984
  • Reasons why kidneys removed for transplantation are not transplanted in the United States..  38:691-694. 1984
  • Cadaver renal transplantation ignoring peak-reactive sera in patients with markedly decreasing pretransplant sensitization..  38:119-124. 1984
  • Influence of changes in pretransplant sensitization on patient and graft survival in cadaver renal transplantation..  38:124-129. 1984
  • The influence of pretransplant transfusions, using different blood products, on patient sensitization and renal allograft survival..  37:350-356. 1984
  • Recovery of in vivo cellular immunity after human marrow grafting. Influence of time postgrafting and acute graft-versus-host disease..  37:145-150. 1984
  • Mycobacterial infections in marrow transplant patients..  36:509-513. 1983
  • Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation..  36:252-255. 1983
  • Transplantation for polycystic kidney disease..  36:54-59. 1983
  • Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease..  35:441-446. 1983
  • Comparative effects of pregnancy, transfusion, and prior graft rejection on sensitization and renal transplant results..  34:360-366. 1982
  • Fate of four cadaveric donor renal allografts with mesangial IgA deposits..  33:370-376. 1982
  • Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy..  33:143-149. 1982
  • Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft-versus-host disease in humans..  33:168-173. 1982
  • Allotransplantation of insulinoma into the testis of diabetic rats..  32:227-232. 1981
  • Immunological consequences of transplanting rat insulinomas..  30:16-22. 1980
  • Creation and properties of histocompatibility antigen-cell conjugates. I. Preparation and immunological properties of rat histocompatibility antigens..  29:444-448. 1980
  • Creation and properties of histocompatibility antigen-cell conjugates. II. Antibody tolerance after treatment with donor histocompatibility antigen chemically coupled to recipient spleen cells..  29:449-453. 1980
  • Transplantation in miniature swine. VI. Factors influencing survival of renal allografts..  28:18-23. 1979
  • Factors which have a significant effect on the survival of human skin grafts..  26:194-198. 1978
  • In vivo and in vitro effects of acute graft-versus-host serum in the rat..  23:303-309. 1977
  • Transplantation in miniature swine. II. In vitro parameters of histocompatibility in MSLA homozygous minipigs..  23:271-276. 1977
  • Transplantation in miniature swine. I. Fixation of the major histocompatibility complex..  22:559-567. 1976
  • Histocompatibility testing and mixed lymphocyte culture responses in chimpanzee families..  17:265-271. 1974
  • HL A typing, mixed leukocyte reactivity, and skin graft survival in a family with a recombinant at the HL-1 chromosomal region (major transplantation region)..  15:435-440. 1973
  • Hl-a typing, mixed leukocyte reactivity, and skin graft survival in a family with a recombinant at the hl-1 chromosomal region (Major transplantation region).  11:435-440. 1973
  • Surgical management of metastatic renal carcinoma of the spine.  16:265-271. 1973
  • Immunological studies on eluates from human renal allografts..  13:131-137. 1972
  • Embryonic development of human transplantation antigens..  9:478-486. 1970
  • Transplanted carcinoma in an immunosuppressed patient..  9:71-74. 1970
  • Graft donor selection based upon single locus (haplotype) analysis within families..  6:524-534. 1968
  • A comparison of the leukocyte agglutination and mixed agglutination techniques for detecting human tissue isoantigens..  6:84-90. 1968
  • Human renal transplantation with donor selection by leukocyte typing..  5:Suppl:1024-9. 1967
  • Fractionation studies of human antisera containing leukocyte-agglutinating and cytotoxic isoantibodies.  5:310-316. 1967
  • Nonhuman primates for the study of composite tissue allotransplantation..  83:241. 2007
  • An alternate arterial reconstruction for pancreas transplantation..  77:481-482. 2004
  • Why is it better to transplant the kidney plus another organ?.  74:1370-1371. 2002
  • The effect of TLI and cyclosporine on xenograft survival..  50:1082-1083. 1990
  • Outcomes and Readmissions after Intestinal/Multivisceral Transplantation 2017
  • Severe Rejection of the Intestine Allograft – Regeneration, Re-transplantation or Death? 2017
  • Skin as a harbinger of rejection of underlying structures in VCA: Concordance or discordance? 2016
  • Detecting DILI in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and-2 Studies 2016
  • Is Stereotactic Body Radiotherapy, as a Bridge To Liver Transplantation, as Effective as TACE? 2015
  • Listing for Liver Transplantation of Patients with Hepatocellular Carcinoma Using the Extended Toronto Criteria; an Intention-to-Treat Analysis 2015
  • The Extended Toronto Criteria for Transplantation for Hepatocellular Carcinoma. A Validation Study 2015
  • Discordance Between Small Bowel and Colonic Biopsies Post Intestinal Transplant. 2015
  • Alterations in Esophageal Function Following Lung Transplantation. 2014
  • Costimulation Blockade Prolongs Rejection-Free Survival of Vascularized Composite Allografts in Non-Human Primates. 2014
  • Developing a Nonhuman Primate Model of Sensitization. 2014
  • Dissociation of Anergic Phenotype From the Expression of Anergy-Related Genes in Memory CD4 T Cells. 2014
  • First Experiences With Kidney Transplantation in a Model of Sensitized Rhesus Macaques 2014
  • Hepatitis B Virus Is Associated With Low Rejection Rates Following Liver Transplant Independent of Hepatitis B Immunoglobulin Use. 2014
  • IL-21 Is a Key Regulator Coordinating Multiple Immune Responses in Chronic Allograft Rejection. 2014
  • Impact of Lymphocyte Depleting Antibody(LDA) On Rate of Acute Rejection (AR) in Patients With Delayed Graft Function (DGF). 2014
  • Is the Risk of Acute Rejection Associated With the Use of Induction Immune Suppression? 2014
  • Mitochondrial DNA Can Function as an Endogenous Innate Immune Activator of Alloreactive T Cells. 2014
  • Outcomes in Kidney Transplant Recipients From Older Living Donors. 2014
  • Resource Utilization for Kidney Transplantation From Time of Referral 2014
  • Successful Desensitization With Combination of Costimulation Blockade and Bortezomib Via Regulating Plasma Cells and Follicular Helper T Cells in Sensitized Rhesus Model. 2014
  • Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 2014
  • The Effect of CCR5 Blockade On De Novo DSA and Long-Term Graft Survival in Non-Human Primate AMR Model 2014
  • The Role of Splenic CD4(+)CD25(+) T reg Cells On Alloreactive B Cell Formation and DSA Production in a Murine CAMR Model. 2014
  • Transplant Size Mismatch in Restrictive Lung Disease 2014
  • Unexplained Variation in Center Use of Expanded Criteria Donor Kidney Transplantation in the United States 2014
  • A Simple Tool for Estimating Acute Rejection Risk Prior to Kidney Transplant. 2014
  • Anti-TCR mAb Induces Peripheral Tolerance to Alloantigens and Delays Islet Allograft Rejection in Autoimmune Diabetic NOD Mice. 2014
  • Comparative Effectiveness of Triple Immunosuppressive Therapy Versus Steroid Avoidance or Early Withdrawal Among Kidney Transplant Recipients Over Age 65. 2014
  • Graft and Patient Survival Following Kidney Transplantation in Previous Lung Transplant Recipients. 2014
  • Identification of Specific and Non-Specific HLA Class II Antibodies in Solid Organ Transplantation. 2014
  • Incidence of Delayed Gastric Emptying Following Lung Transplantation. 2014
  • The Effect of Neutralizing BAFF With Atacicept in a T Cell Depletion-Induced Nonhuman Primate AMR Model. 2014
  • The Effect of Cell-Matrix Interaction on Encapsulated Human Islets 2013
  • Co-Stimulatory Blockade and Donor Bone Marrow Cell Infusion for Immunomodulation and Tolerance Induction in Vascularized Composite Allografts - A Large Animal Translational Trial 2012
  • Repeat surgical bowel lengthening with the STEP procedure 2008
  • Anti-CX(3)CR1 antibody treatment prolongs murine cardiac allograft survival. 2000
  • Aseptic necrosis after cadaveric renal transplantation: Data from the UNOS/USRDS database. 2000
  • Blood usage during liver transplantation: The impact of an autotransfusion device. 2000
  • Detection of cells recognizing donor graftderived fibroblasts in the blood of allograftrejecting animals. 2000
  • Evaluation of function following human hand transplantation. 2000
  • Fractures after cadaveric renal transplantation: Data from the UNOS/USRDS database. 2000
  • Human platelets activate porcine endothelial cells through a CD154 dependent mechanism. 2000
  • Immunoregulation in monkey kidney allograft acceptance: Bystander suppression of DTH triggered by donor antigens. 2000
  • Impact of donor and recipient factors on graft survival after cadaveric renal transplantation: Data from the UNOS/USRDS database. 2000
  • Impact of recipient and donor hepatitis C virus infection status on outcomes after renal transplantation: Data from the UNOS/USRDS database. 2000
  • Patient and renal allograft survival in patients seropositive for human immunodeficiency virus infection at transplantation: Data from the UNOS/USRDS database. 2000
  • Pediatric en bloc vs. pediatric single kidneys: Is there a difference? 2000
  • Porcine endothelium costimulates human T cells in the absence of human antigen presenting cells (APCs). 2000
  • Primary skin allograft acceptance with anti-CD154 in a non-human primate model. 2000
  • Skin allograft acceptance in long-surviving non-human primate renal allograft recipients treated with FN18-CRM9. 2000
  • Successful conversion from conventional immunosuppression to anti-CD40 ligand therapy in a non-human primate model. 2000
  • The calcineurin inhibitors cyclosporine A and FK506 potentiate T cell receptor-induced expression of LAT, a molecule essential for T cell activation and development. 2000
  • Treatment of steroid resistant rejection with a novel anti B-cell preparation, rituximab. 2000
  • Type 2 angiotensin II receptor mRNA expression in human renal allografts is associated with chronic rejection. 2000
  • CAUSES OF LATE MORTALITY IN SURVIVORS OF LIVER TRANSPLANTATION. 1999
  • CORRELATION OF EPSTEIN-BARR VIRAL LOAD WITH DEVELOPMENT OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS 1999
  • ISOLATED LIVER TRANSPLANTATION IN INFANTS WITH TOTAL PARENTERAL NUTRITION ASSOCIATED END-STAGE LIVER DISEASE 1999
  • LONG-TERM INTRAHEPATIC ISLET ALLOGRAFT SURVIVAL IN NON-HUMAN PRIMATES TREATED WITH ANTI-CD154 MONOTHERAPY 1999
  • PREVENTION OF HYPERACUTE REJECTION OF PIG XENOGRAFTS BY SURROGATE TOLEROGENESIS. 1999
  • CLONING OF PORCINE CD80 AND CHARACTERIZATION OF HUMAN T CELL COSTIMULATORY ACTIVITY 1999
  • COLIGATION OF CD40L (CD154) AND CD3 RESULTS IN CD4+ T CELL ACTIVATION AND THE INDUCTION OF APOPTOSIS. 1999
  • RHESUS RENAL ALLOGRAFTS CONTAIN NON-DESTRUCTIVE ACTIVATED LYMPHOCYTIC INFILTRATES FOLLOWING ANTI-CD154 THERAPY. 1999
  • STABILITY OF THE TOLERANCE PHENOTYPE AFTER WITHDRAWAL OF IMMUNOSUPPRESSIVE DRUG THERAPY: INFLUENCE OF LOCAL AND GENETIC FACTORS INFLUENCING TNFα AND TGFβ EXPRESSION 1999
  • THE FATE OF XENOREACTIVE ANTIBODIES IN SWINE-TO-PRIMATE LUNG TRANSPLANTS 1999
  • UNIQUE CYTOKINE GENOTYPES ASSOCIATED WITH CHRONIC REJECTION AND CHRONIC REJECTION-FREE STATES IN HEART RECIPIENTS. 1999
  • XENOREACTIVE ANTIBODY RECOGNITION OF RELEVANT ANTIGENS IN SWINE KIDNEY AND LUNG 1999
  • Sequential measurement of peripheral blood allogeneic microchimerism levels and association with pulmonary function. 1996
  • Tacrolimus in pediatric renal transplantation. 1996